Developer docs
API playgroundTry for free, no card

Search company profiles

Karus Therapeutics

Full company profile

uuid000bsax

Namestring
Karus Therapeutics
Company typeenum
Private
Founded yearint
2005
Short descriptiontext

Karus Therapeutics is a privately held, UK-based pharmaceutical company founded in 2005 that designs and develops molecular-targeted small-molecule drugs to treat cancer, operating as an early-stage oncology drug discovery entity with no commercial product yet disclosed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChilworth, United Kingdom
HQ citystring
Chilworth
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cancer drug discovery, small molecule therapeutics, molecular targeted oncology, pharmaceutical R&D, oncology drug development
Industry1 code
PRIMARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Pharmaceuticals
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Karus Therapeutics is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer. Its work centers on discovering and advancing small-molecule oncology candidates from research through development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Molecular-targeted small-molecule oncology drug candidates
CategoryOncology Pharmaceuticals / Small-Molecule Therapeutics
Description

A pipeline of small-molecule, molecularly targeted drug candidates designed to treat cancer. Intended for eventual out-licensing, partnership, or acquisition by larger pharmaceutical companies to advance into clinical development.

No data
Peers10 records
TypeDirect peer
Description

Originally a UK-based small molecule structure-based drug discovery company focused on oncology and CNS; highly comparable given shared UK roots, SBDD heritage, and oncology focus.

TypeDirect peer
Description

UK-based small molecule drug discovery and development company with oncology and fibrosis programs; direct comparable in geography, modality, and small-cap biotech structure.

TypeEmerging player
Description

Europe-based small molecule discovery and development CRO/emerging sponsor with oncology portfolio; comparable as a smaller-scale small molecule oncology developer with services business underpinning.

TypeDirect peer
Description

Clinical-stage oncology company developing small molecule nucleotide analogues (ProTide technology); directly comparable as a small-cap targeted oncology developer.

TypeDirect peer
Description

Clinical-stage small molecule oncology company developing targeted therapies (e.g., PRIMA-1MET for p53 reactivation); direct functional analogue as a small-cap, target-focused cancer drug developer.

TypeDirect peer
Description

UK-based targeted therapeutics company with oncology pipeline built around a proprietary small molecule–like scaffold; comparable UK small-cap oncology developer.

TypeDirect peer
Description

Clinical-stage small molecule oncology company developing CDK inhibitors and related targeted drugs; directly comparable in modality, stage profile, and small-cap funding scale.

8Syros Pharmaceuticals
TypeDirect peer
Description

Small molecule oncology company focused on cell-cycle and transcriptional regulation; comparable development-stage peer in targeted cancer drug discovery with similar capital profile.

TypeDirect peer
Description

UK-based small molecule drug discovery company focused on cancer and autoimmune disease; strong direct peer given shared geography, modality (small molecules), and development-stage status.

10Astex Pharmaceuticals
TypeBroad incumbent
Description

UK-based structure-based small molecule drug discovery company with broad oncology programs, acquired by Otsuka; broader incumbent peer in the same UK small-molecule oncology niche.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Karus Therapeutics

Oncology Pharmaceuticalskarustherapeutics.com

Karus Therapeutics is a privately held, UK-based pharmaceutical company founded in 2005 that designs and develops molecular-targeted small-molecule drugs to treat cancer, operating as an early-stage oncology drug discovery entity with no commercial product yet disclosed.

Karus Therapeutics firmographics

Firmographics
Name
Karus Therapeutics
Website
https://karustherapeutics.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Karus Therapeutics is a privately held, UK-based pharmaceutical company founded in 2005 that designs and develops molecular-targeted small-molecule drugs to treat cancer, operating as an early-stage oncology drug discovery entity with no commercial product yet disclosed.
Ownership category
akta.pro rank

Karus Therapeutics industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology

Keywords

  • Cancer drug discovery
  • Small molecule therapeutics
  • Molecular targeted oncology
  • Pharmaceutical R&D
  • Oncology drug development

Where Karus Therapeutics is headquartered

Location

Headquarters

HQ city
Chilworth
HQ country
United Kingdom
HQ region
Europe

Markets served

Karus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Karus Therapeutics product offering

Product offering

Core offering

Karus Therapeutics is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer. Its work centers on discovering and advancing small-molecule oncology candidates from research through development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular-targeted small-molecule oncology drug candidates A pipeline of small-molecule, molecularly targeted drug candidates designed to treat cancer. Intended for eventual out-licensing, partnership, or acquisition by larger pharmaceutical companies to advance into clinical development.

Companies that use Karus Therapeutics

Customer profile

Ideal customer profiles1 record

Karus Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Karus Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vernalis (now HitGen): Originally a UK-based small molecule structure-based drug discovery company focused on oncology and CNS; highly comparable given shared UK roots, SBDD heritage, and oncology focus.
  • Redx Pharma: UK-based small molecule drug discovery and development company with oncology and fibrosis programs; direct comparable in geography, modality, and small-cap biotech structure.
  • NuCana: Clinical-stage oncology company developing small molecule nucleotide analogues (ProTide technology); directly comparable as a small-cap targeted oncology developer.
  • Aprea Therapeutics: Clinical-stage small molecule oncology company developing targeted therapies (e.g., PRIMA-1MET for p53 reactivation); direct functional analogue as a small-cap, target-focused cancer drug developer.
  • Bicycle Therapeutics: UK-based targeted therapeutics company with oncology pipeline built around a proprietary small molecule–like scaffold; comparable UK small-cap oncology developer.
  • Cyclacel Pharmaceuticals: Clinical-stage small molecule oncology company developing CDK inhibitors and related targeted drugs; directly comparable in modality, stage profile, and small-cap funding scale.
  • Syros Pharmaceuticals: Small molecule oncology company focused on cell-cycle and transcriptional regulation; comparable development-stage peer in targeted cancer drug discovery with similar capital profile.
  • Sareum Holdings: UK-based small molecule drug discovery company focused on cancer and autoimmune disease; strong direct peer given shared geography, modality (small molecules), and development-stage status.

Emerging players

  • Selvita: Europe-based small molecule discovery and development CRO/emerging sponsor with oncology portfolio; comparable as a smaller-scale small molecule oncology developer with services business underpinning.

Broad incumbents

  • Astex Pharmaceuticals: UK-based structure-based small molecule drug discovery company with broad oncology programs, acquired by Otsuka; broader incumbent peer in the same UK small-molecule oncology niche.

Market position

Customer concentration

Karus Therapeutics social profiles

Digital presence

Karus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Karus Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Karus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Karus Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karus Therapeutics

What does Karus Therapeutics do?

Karus Therapeutics is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer. Its work centers on discovering and advancing small-molecule oncology candidates from research through development.

When was Karus Therapeutics founded?

Karus Therapeutics was founded in 2005. It employs 11 to 50 people.

Where is Karus Therapeutics based?

Karus Therapeutics is headquartered in Chilworth, United Kingdom, in the Europe region.

Who are Karus Therapeutics's main competitors?

Direct peers on record are Vernalis (now HitGen), Redx Pharma, NuCana, Aprea Therapeutics, Bicycle Therapeutics, Cyclacel Pharmaceuticals, Syros Pharmaceuticals and Sareum Holdings. Selvita is listed as an emerging player. Astex Pharmaceuticals is listed as a broad incumbent.

Does Karus Therapeutics have an API?

No public API is recorded for Karus Therapeutics.

What industry is Karus Therapeutics in?

Karus Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals